Galapagos NV (GLPG.AS)
EUR 25.7
(0.78%)
EUR 25.7
(0.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 239.72 Million EUR | -52.56% |
| 2022 | 505.28 Million EUR | 4.21% |
| 2021 | 484.84 Million EUR | 1.42% |
| 2020 | 478.05 Million EUR | -43.42% |
| 2019 | 844.98 Million EUR | 192.55% |
| 2018 | 288.83 Million EUR | 127.27% |
| 2017 | 127.08 Million EUR | -1.88% |
| 2016 | 129.51 Million EUR | 227.37% |
| 2015 | 39.56 Million EUR | -42.97% |
| 2014 | 69.36 Million EUR | -49.62% |
| 2013 | 137.69 Million EUR | 1.05% |
| 2012 | 136.26 Million EUR | 42.11% |
| 2011 | 95.88 Million EUR | -21.67% |
| 2010 | 122.41 Million EUR | 31.5% |
| 2009 | 93.08 Million EUR | 20.93% |
| 2008 | 76.97 Million EUR | 16.75% |
| 2007 | 65.93 Million EUR | 87.57% |
| 2006 | 35.15 Million EUR | 212.74% |
| 2005 | 11.24 Million EUR | 44.53% |
| 2004 | 7.77 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 59.84 Million EUR | -23.15% |
| 2024 Q2 | 77.87 Million EUR | 24.73% |
| 2024 Q1 | 62.43 Million EUR | 129.85% |
| 2023 Q2 | 149.95 Million EUR | -16.17% |
| 2023 FY | 239.7 Million EUR | -52.56% |
| 2023 Q1 | 178.86 Million EUR | 88.04% |
| 2023 Q4 | -209.12 Million EUR | -274.23% |
| 2023 Q3 | 120.02 Million EUR | -19.96% |
| 2022 Q3 | 136.2 Million EUR | -1.02% |
| 2022 Q1 | 136.34 Million EUR | -18.35% |
| 2022 Q2 | 137.6 Million EUR | 0.93% |
| 2022 Q4 | 95.12 Million EUR | -30.16% |
| 2022 FY | 505.28 Million EUR | 4.21% |
| 2021 Q4 | 166.98 Million EUR | 160.13% |
| 2021 FY | 484.84 Million EUR | 1.42% |
| 2021 Q1 | 113.89 Million EUR | -21.16% |
| 2021 Q2 | 139.77 Million EUR | 22.72% |
| 2021 Q3 | 64.19 Million EUR | -54.07% |
| 2020 Q4 | 144.46 Million EUR | 9.6% |
| 2020 FY | 478.05 Million EUR | -43.42% |
| 2020 Q3 | 131.81 Million EUR | 27.24% |
| 2020 Q2 | 103.6 Million EUR | 5.53% |
| 2020 Q1 | 98.17 Million EUR | -17.69% |
| 2019 Q2 | 58.73 Million EUR | 77.74% |
| 2019 FY | 844.98 Million EUR | 192.55% |
| 2019 Q4 | 119.26 Million EUR | -81.19% |
| 2019 Q1 | 33.04 Million EUR | -68.93% |
| 2019 Q3 | 633.93 Million EUR | 979.26% |
| 2018 FY | 288.83 Million EUR | 127.27% |
| 2018 Q2 | 49.67 Million EUR | 31.05% |
| 2018 Q3 | 94.87 Million EUR | 90.99% |
| 2018 Q1 | 37.9 Million EUR | -3.34% |
| 2018 Q4 | 106.37 Million EUR | 12.13% |
| 2017 Q3 | 26.94 Million EUR | 0.04% |
| 2017 FY | 127.08 Million EUR | -1.88% |
| 2017 Q2 | 26.93 Million EUR | -20.77% |
| 2017 Q1 | 33.99 Million EUR | -57.25% |
| 2017 Q4 | 39.21 Million EUR | 45.54% |
| 2016 Q4 | 79.5 Million EUR | 609.08% |
| 2016 Q2 | 28.67 Million EUR | 183.35% |
| 2016 FY | 129.51 Million EUR | 227.37% |
| 2016 Q1 | 10.12 Million EUR | 40.71% |
| 2016 Q3 | 11.21 Million EUR | -60.9% |
| 2015 Q4 | 7.19 Million EUR | 26.06% |
| 2015 Q1 | 14.79 Million EUR | -26.91% |
| 2015 FY | 39.56 Million EUR | -42.97% |
| 2015 Q3 | 5.7 Million EUR | -51.93% |
| 2015 Q2 | 11.86 Million EUR | -19.8% |
| 2014 Q1 | 22.52 Million EUR | -4.85% |
| 2014 FY | 69.36 Million EUR | -49.62% |
| 2014 Q4 | 20.24 Million EUR | 48.16% |
| 2014 Q3 | 13.66 Million EUR | -39.34% |
| 2014 Q2 | 22.52 Million EUR | 0.0% |
| 2013 Q3 | 23.67 Million EUR | -3.8% |
| 2013 Q4 | 23.67 Million EUR | 0.0% |
| 2013 Q2 | 24.61 Million EUR | 0.0% |
| 2013 Q1 | 24.61 Million EUR | 240.63% |
| 2013 FY | 137.69 Million EUR | 1.05% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | -17.5 Million EUR | -139.54% |
| 2012 FY | 136.26 Million EUR | 42.11% |
| 2012 Q3 | 44.25 Million EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | 95.88 Million EUR | -21.67% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 FY | 122.41 Million EUR | 31.5% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | 93.08 Million EUR | 20.93% |
| 2008 FY | 76.97 Million EUR | 16.75% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | 65.93 Million EUR | 87.57% |
| 2006 FY | 35.15 Million EUR | 212.74% |
| 2005 FY | 11.24 Million EUR | 44.53% |
| 2004 FY | 7.77 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -5066.466% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -5087.708% |
| Adocia SA | 2.15 Million EUR | -11049.953% |
| Aelis Farma SA | 9.05 Million EUR | -2547.714% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -7507.871% |
| genOway Société anonyme | 20.04 Million EUR | -1095.847% |
| IntegraGen SA | 12.53 Million EUR | -1812.066% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -79798.945% |
| Neovacs S.A. | 533.41 Thousand EUR | -44841.621% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -14156.429% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -1210871.914% |
| Sensorion SA | 4.74 Million EUR | -4954.201% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -80797.375% |
| TME Pharma N.V. | 17 Thousand EUR | -1410041.176% |
| Valbiotis SA | 4.73 Million EUR | -4964.948% |
| TheraVet SA | 1.07 Million EUR | -22136.713% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -13218.0% |
| argenx SE | 1.13 Billion EUR | 78.866% |
| BioSenic S.A. | 543 Thousand EUR | -44048.066% |
| Celyad Oncology SA | 102 Thousand EUR | -234923.529% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Genfit S.A. | 28.56 Million EUR | -739.223% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -11386.536% |
| Innate Pharma S.A. | 51.9 Million EUR | -361.887% |
| Inventiva S.A. | 17.47 Million EUR | -1271.654% |
| MaaT Pharma SA | 2.22 Million EUR | -10659.605% |
| MedinCell S.A. | 9.16 Million EUR | -2517.074% |
| Nanobiotix S.A. | 30.05 Million EUR | -697.538% |
| Onward Medical N.V. | 532 Thousand EUR | -44960.902% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -1589.195% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -10664.436% |
| Oxurion NV | 263 Thousand EUR | -91049.81% |
| Pharming Group N.V. | 245.31 Million EUR | 2.28% |
| Poxel S.A. | 1.98 Million EUR | -12001.161% |
| GenSight Biologics S.A. | 1.26 Million EUR | -18820.6% |
| Transgene SA | 1.18 Million EUR | -20146.959% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 95.436% |
| Valneva SE | 153.71 Million EUR | -55.957% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 6722.21% |